Immune Effect of Co-Culture of Dendritic Cells and Cytokine-Induced Killer Cells on Prostate Cancer Cells

Overview

Journal Cell Biochem Biophys

Specialties Biochemistry
Biophysics
Cell Biology

Date 2024 Oct 24

PMID 39448420

Authors

Yaojun Li

Shanmiao Chen

Shoulei Liu

Affiliations

Soon will be listed here.

Abstract

It was to explore the immune outcome of co-culture of dendritic cells (DC) and cytokine-induced killer cells (CIK) on prostate cancer (PCa) cells. Peripheral blood mononuclear cells (PBMCs) were extracted from healthy blood donors. DC and CIK cells were induced and co-cultured. The proliferation and phenotypic changes of DC, CIK, and DC-CIK cells/groups were observed. Model rats were constructed by injecting PC3 PCa cells into the abdominal cavity. The successful 50 cases were divided into a negative control group, a chemotherapy group, a DC group, a CIK group, and a DC-CIK treatment group (each consisting of 10 rats) to observe tumor progression. The secreted concentrations of interleukin-12 (IL-12) ((103.67 ± 2.77) pg/mL) and interferon-γ (IFN-γ) ((730.09 ± 23.52) pg/mL) were higher in DC-CIK group as against DC and CIK groups; the proliferation of CIK was higher in DC-CIK group as against CIK within 12 to 20 days of culture. The positive rate (PR) of CD3/ CD56 and CD8 was higher and that of CD45RA was lower in DC-CIK group as against CIK.The killing rate of the DC-CIK group was higher than that of the DC and CIK groups at a target effect ratio of 10:1/20:1/50:1 (P < 0.05). After the treatment, the body weight of rats in the chemotherapy group, DC group, and CIK group was significantly reduced (P < 0.05), while no significant changes were observed in the negative control group and DC-CIK group (P > 0.05). After 25 days of treatment, the tumor size in the DC-CIK group was significantly smaller compared to the negative control group, chemotherapy group, DC group, and CIK group; the necrotic area of the tumor tissue in the DC-CIK group was also significantly larger than that in the negative control group, chemotherapy group, DC group, and CIK group (P < 0.05). Co-culture of DC and CIK is excellent in enhancing the proliferation of CIK cells, increasing the secretion of IL-12 and IFN-γ, and enhancing the activity of immune cells and anti-tumor ability, showing its potential in anti-PCa tumor immunotherapy.

References

Zapala P, Garbas K, Lewandowski Z, Slusarczyk A, Slusarczyk C, Mielczarek L . Neutrophil-to-lymphocyte ratio predicts nodal involvement in unfavourable, clinically nonmetastatic prostate cancer patients and overall survival in pN1 patients. Sci Rep. 2023; 13(1):392. PMC: 9829873. DOI: 10.1038/s41598-023-27542-2. View

Vandekerkhove G, Chi K, Wyatt A . Clinical utility of emerging liquid biomarkers in advanced prostate cancer. Cancer Genet. 2017; 228-229:151-158. DOI: 10.1016/j.cancergen.2017.08.003. View

Wu J, Guo S, Wang L, Liao Z . Correlation analysis between CD133, Klk3 and grhl2 expression and tumor characteristics in prostate cancer. Cell Mol Biol (Noisy-le-grand). 2022; 67(6):68-73. DOI: 10.14715/cmb/2021.67.6.10. View

Gloger S, Ubrig B, Boy A, Leyh-Bannurah S, Siemer S, Arndt M . Bilateral Peritoneal Flaps Reduce Incidence and Complications of Lymphoceles after Robotic Radical Prostatectomy with Pelvic Lymph Node Dissection-Results of the Prospective Randomized Multicenter Trial ProLy. J Urol. 2022; 208(2):333-340. PMC: 9275839. DOI: 10.1097/JU.0000000000002693. View

Nicolopoulos K, Moshi M, Stringer D, Ma N, Jenal M, Vreugdenburg T . The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network.... Arch Osteoporos. 2023; 18(1):18. DOI: 10.1007/s11657-023-01211-3. View

Liu H . Expression and potential immune involvement of cuproptosis in kidney renal clear cell carcinoma. Cancer Genet. 2023; 274-275:21-25. DOI: 10.1016/j.cancergen.2023.03.002. View

Chamoto K, Wakita D, Narita Y, Zhang Y, Noguchi D, Ohnishi H . An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy. Cancer Res. 2006; 66(3):1809-17. DOI: 10.1158/0008-5472.CAN-05-2246. View

Yan X, Dong Q, Jin G, Zhu Y, Zhang L . Effect of Interleukin-17 gene on glomerular ultrastructure and podocyte injury in adriamycin nephropathy rat models. J Biol Regul Homeost Agents. 2021; 35(3):1001-1010. DOI: 10.23812/20-741-A. View

Golay J, Martinelli S, Alzani R, Cribioli S, Albanese C, Gotti E . Cord blood-derived cytokine-induced killer cells combined with blinatumomab as a therapeutic strategy for CD19 tumors. Cytotherapy. 2018; 20(8):1077-1088. DOI: 10.1016/j.jcyt.2018.06.003. View

10.

Zhou L, Chen Q, Chen H, Wang L, Zhang J . Enhanced Inhibitory Effect of DC-CIK Cells on Lung Adenocarcinoma via Anti-Tim-3 Antibody and Antiprogrammed Cell Death-1 Antibody and Possible Mechanism. Evid Based Complement Alternat Med. 2022; 2022:4097576. PMC: 9357700. DOI: 10.1155/2022/4097576. View

11.

Chomchoei C, Brimson J, Brimson S . Repurposing fluoxetine to treat lymphocytic leukemia: Apoptosis induction, sigma-1 receptor upregulation, inhibition of IL-2 cytokine production, and autophagy induction. Expert Opin Ther Targets. 2023; 26(12):1087-1097. DOI: 10.1080/14728222.2022.2166829. View

12.

Naseer F, Ahmad T, Kousar K, Kakar S, Gul R, Anjum S . Formulation for the Targeted Delivery of a Vaccine Strain of Oncolytic Measles Virus (OMV) in Hyaluronic Acid Coated Thiolated Chitosan as a Green Nanoformulation for the Treatment of Prostate Cancer: A Viro-Immunotherapeutic Approach. Int J Nanomedicine. 2023; 18:185-205. PMC: 9838128. DOI: 10.2147/IJN.S386560. View

13.

Huang R, Li Y, Wu H, Liu B, Zhang X, Zhang Z . Ga-PSMA-11 PET/CT versus Ga-PSMA-11 PET/MRI for the detection of biochemically recurrent prostate cancer: a systematic review and meta-analysis. Front Oncol. 2023; 13:1216894. PMC: 10461474. DOI: 10.3389/fonc.2023.1216894. View

14.

Gao Y, Liu Y, Liu Y, Peng Y, Yuan B, Fu Y . UHRF1 promotes androgen receptor-regulated CDC6 transcription and anti-androgen receptor drug resistance in prostate cancer through KDM4C-Mediated chromatin modifications. Cancer Lett. 2021; 520:172-183. DOI: 10.1016/j.canlet.2021.07.012. View

15.

Lu M, Wei F, Ma S, Xu Z, Wang J, Yang C . Oncolytic Virus as a Novel Modality for the Treatment of Prostate Cancer. Discov Med. 2022; 32(167):133-139. View

16.

Kim K, Choi B, Choi H, Ko M, Kim D, Kim D . Enhanced natural killer cell anti-tumor activity with nanoparticles mediated ferroptosis and potential therapeutic application in prostate cancer. J Nanobiotechnology. 2022; 20(1):428. PMC: 9523925. DOI: 10.1186/s12951-022-01635-y. View

17.

Dong Y, Gao S, Zhang X, Kou J, Liu J, Ye T . CCL17 and CCL22 induce CCR4 receptor expression and promote cytokine-induced killer cells migration. Anticancer Drugs. 2021; 33(2):149-157. DOI: 10.1097/CAD.0000000000001256. View

18.

Zhang Z, Xiong L, Wu Z, Liu H, Ning K, Peng Y . Neoadjuvant combination of pazopanib or axitinib and programmed cell death protein-1-activated dendritic cell-cytokine-induced killer cells immunotherapy may facilitate surgery in patients with renal cell carcinoma. Transl Androl Urol. 2021; 10(5):2091-2102. PMC: 8185689. DOI: 10.21037/tau-21-406. View

19.

Chen S, Yang Y, Jiao Y, Sun H, Yan Z . Capecitabine metronomic chemotherapy combined with autologous CIK cell immunotherapy in the treatment of recurrent and metastatic triple-negative breast cancer. J BUON. 2021; 26(3):734-740. View

20.

Xu H, Qin W, Feng H, Song D, Yang X, Zhang J . Analysis of the Clinical Efficacy of Dendritic Cell -cytokine Induced Killer Cell-based Adoptive Immunotherapy for Colorectal Cancer. Immunol Invest. 2020; 50(6):622-633. DOI: 10.1080/08820139.2020.1781881. View